Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 5/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360711 | 1.00 | TAAR1 (0.43) | TAAR1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30360682 | 1.00 | TAAR1 (0.43) | TAAR1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL32670720 | 1.00 | TAAR1 (0.43) | TAAR1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19813055 | 1.00 | TAAR1 (0.43) | TAAR1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19813086 | 1.00 | TAAR1 (0.43) | TAAR1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31071012 | 0.90 | TAAR1 (0.44) | TAAR1MTNR1AMTNR1BKEAP1DRD1 | |
| SCHEMBL19821165 | 0.83 | MTNR1A (0.46) | TAAR1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19812782 | 0.82 | TAAR1 (0.47) | TAAR1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19812780 | 0.82 | TAAR1 (0.47) | TAAR1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL32670725 | 0.82 | TAAR1 (0.47) | TAAR1CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4464317-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sumitomo Pharma America, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3494119-B1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-11958862-B2 | Compounds and compositions and uses thereof | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-27 | — | — | US | disclosed |
| US-10927124-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190308990-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3494119-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10196403-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| WO-2018023072-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018023072-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196403-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | TAAR1 893/4885CHRNB2 139/4885CHRNB4 275/4885 |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | TAAR1 893/4885CHRNB2 139/4885CHRNB4 275/4885 |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | TAAR1 97/4885CHRNB2 314/4885CHRNB4 429/4885 |
| US-10927124-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | TAAR1 893/4885CHRNB2 139/4885CHRNB4 275/4885 |
| US-11958862-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | TAAR1 893/4885CHRNB2 139/4885CHRNB4 275/4885 |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | TAAR1 893/4885CHRNB2 139/4885CHRNB4 275/4885 |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | TAAR1 893/4885CHRNB2 139/4885CHRNB4 275/4885 |
| US-20190308990-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | TAAR1 893/4885CHRNB2 139/4885CHRNB4 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.